NCT04678401
IS-free Treg HaploHCT
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 13 versions: 9 with changes below, 4 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 17 words
- Enrollment closed, study ongoing
- Secondary endpoints: details revised at 2 of 9 entries
- Site details revised
Notable Enrollment target: 20 to 30v12 Show 6 more changesShow less
- Primary completion date: Dec 31, 2029 to Aug 31, 2028
- Eligibility criteria expanded, about 56 words
- Study completion date: Dec 31, 2030 to Aug 31, 2029
- Interventions: CD34+ Haplo Peripheral Blood Stem Cell (Procedure), Cyclophosphamide (Drug), Fludarabine (Drug), Mesna (Drug), Radiation (Radiation)… to CD34+ Haplo Peripheral Blood Stem Cell (Procedure), Cyclophosphamide (Drug), Fludarabine (Drug), Melphalan (Drug), Mesna (Drug), Radiation…
- Study arms: 2 to 3
- Study description shortened, about 3 words
- Notable Primary completion date: Dec 31, 2025 to Dec 31, 2029
- Study completion date: Dec 31, 2027 to Dec 31, 2030
- Minor Primary completion date: Oct 31, 2025 to Dec 31, 2025
- Study completion date: Oct 31, 2027 to Dec 31, 2027
Notable Enrollment target: 10 to 20v7 Show 5 more changesShow less
- Primary completion date: Dec 31, 2023 to Oct 31, 2025
- Eligibility criteria expanded, about 28 words
- Study completion date: Dec 31, 2024 to Oct 31, 2027
- Study description revised
- Study arms: 1 to 2
Show 3 earlier versionsHide 3 earlier versions
- Notable Primary completion date: Dec 31, 2022 to Dec 31, 2023
- Study completion date: Dec 31, 2023 to Dec 31, 2024
- Notable Primary completion date: Oct 31, 2021 to Dec 31, 2022
- Study completion date: Oct 31, 2023 to Dec 31, 2023
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Jan 2021 to Jan 12, 2021
- Site details revised
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (9)
Show 4 moreShow less
Arms and interventions
Please note that this arm is closed due to meeting accrual goal as of June 2024. This arm (Cohort A) included patients with rel/ref AML/MDS, with active disease despite at least 1 prior line of therapy. Treatment plan and follow up schedule: Day -15 to -6: Myeloablative conditioning regimen Radiation: Total Myeloid and Lymphoid Irradiation (TMLI) on Days -15 to -11 OR Total Body Irradiation (TBI) on Days -13 to -11 Chemotherapy: Fludarabine on Days -10 to -6, Thiotepa on Days -10 to -9, and Cyclophosphamide and Mesna on Days -8 and -7 Day -4: Treg-enriched donor cell infusion and GVHD assessment Day -1: Unmodified donor T Cell infusion and GVHD assessment Day 0: CD34+ Haplo Peripheral Blood Stem Cell Transplant and GVHD assessment Days 30, 60, 100, 180, 365 post-HSCT, participants will undergo testing and assessment of minimal residual disease (MRD) and (GVHD).
This arm (Cohort B) includes patients with ultra-high-risk AML/MDS that meets the definition of "Myeloid Neoplasms with mutated TP53" per the 2022 International Consensus Classification, regardless of remission status at the time of transplant. Treatment plan and follow up schedule: Day -15 to -6: Myeloablative conditioning regimen Radiation: Total Myeloid and Lymphoid Irradiation (TMLI) on Days -15 to -11 OR Total Body Irradiation (TBI) on Days -13 to -11 Chemotherapy: Fludarabine on Days -10 to -6, Thiotepa on Days -10 to -9, and Cyclophosphamide and Mesna on Days -8 and -7 Day -4: Treg-enriched donor cell infusion and GVHD assessment Day -1: Unmodified donor T Cell infusion and GVHD assessment Day 0: CD34+ Haplo Peripheral Blood Stem Cell Transplant and GVHD assessment Days 30, 60, 100, 180, 365 post-HSCT, participants will undergo testing and assessment of minimal residual disease (MRD) and (GVHD).
This arm (Cohort C) includes patients with ultra-high-risk AML/MDS that meets definition of 'Myeloid Neoplasms with multi-hit or complex karyotype (CK+) mutated TP53' per 2022 International Consensus Classification, with response (AML with \<5% BM blasts/MDS with \<10% BM blasts). Treatment plan and follow up schedule: Day -11 to -5: Reduced intensity conditioning regimen Chemotherapy: Thiotepa on Day -11, Fludarabine on Days -10 to -7, and Melphalan on Day -6 Radiation: Total Body Irradiation (TBI) on Day -5 Day -4: Treg-enriched donor cell infusion and GVHD assessment Day -1: Unmodified donor T Cell infusion and GVHD assessment Day 0: CD34+ Haplo Peripheral Blood Stem Cell Transplant and GVHD assessment Days 30, 60, 100, 180, 365 post-HSCT, participants will undergo testing and assessment of minimal residual disease (MRD) and (GVHD).
Radiation: Radiation
Drugs: Fludarabine, Thiotepa, Cyclophosphamide, Mesna, Melphalan
Biologicals: Treg-enriched donor cell, Unmodified donor T Cell
Procedures: CD34+ Haplo Peripheral Blood Stem Cell
Sites
1 site in 1 country
- Dana Farber Cancer InstituteBoston, Massachusetts, United States